MCID: ADN012
MIFTS: 44

Adenocarcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Adenocarcinoma in Situ

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4943
MeSH 44 D065311
NCIt 50 C4123
SNOMED-CT 68 51642000
UMLS 73 C0334276

Summaries for Adenocarcinoma in Situ

MalaCards based summary : Adenocarcinoma in Situ is related to endometrial adenocarcinoma and endometrial mucinous adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and testes, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Adenocarcinoma in Situ

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 endometrial adenocarcinoma 30.4 CDKN2A KRAS KRT7
2 endometrial mucinous adenocarcinoma 30.3 CDKN2A PAX2
3 villous adenoma 29.9 CDX2 KRAS KRT20
4 cystic teratoma 29.9 CDX2 KRT20 KRT7
5 papillary carcinoma 29.9 KRT20 KRT7 PAX8
6 cervical adenocarcinoma 29.7 CDKN1A CDKN2A CDX2 KRT20 KRT7
7 lung cancer susceptibility 3 29.6 CDKN2A CDX2 KRAS KRT20 KRT7
8 mucinous adenocarcinoma 29.3 CDKN2A CDX2 KRAS KRT20 KRT7
9 endocervical adenocarcinoma 29.1 CDKN2A CDX2 KRT20 KRT7 PAX2 PAX8
10 in situ pulmonary adenocarcinoma 11.1
11 inverted transitional papilloma 10.8 CDKN2A KRT7
12 adenocarcinoma 10.8
13 ovary neuroendocrine neoplasm 10.8 CDX2 KRT7
14 adenoid basal cell carcinoma 10.7 CDKN2A KRT7
15 endosalpingiosis 10.7 KRT7 PAX8
16 renal pelvis adenocarcinoma 10.7 KRT7 PAX8
17 bladder carcinoma in situ 10.7 CDKN2A KRT7
18 mucinous adenofibroma 10.7 CDX2 KRT7
19 anus adenocarcinoma 10.7 CDX2 KRT7
20 cystic basal cell carcinoma 10.7 KRT20 KRT7
21 seminal vesicle adenocarcinoma 10.7 KRT20 KRT7
22 transverse colon cancer 10.7 KRT20 KRT7
23 ovarian large-cell neuroendocrine carcinoma 10.7 KRT20 KRT7
24 eyelid neoplasm 10.7 KRT20 KRT7
25 well-differentiated liposarcoma 10.7 CDKN2A KRT7
26 malignant syringoma 10.7 KRT20 KRT7
27 epithelial predominant wilms' tumor 10.7 CDX2 KRT7
28 krukenberg carcinoma 10.7 KRT20 KRT7
29 large intestine adenocarcinoma 10.7 KRT20 KRT7
30 linitis plastica 10.7 KRT20 KRT7
31 lung acinar adenocarcinoma 10.7 KRT20 KRT7
32 small cell carcinoma of the bladder 10.7 KRT20 KRT7
33 adenoid squamous cell carcinoma 10.7 KRT20 KRT7
34 eccrine sweat gland neoplasm 10.7 KRT20 KRT7
35 rete testis adenoma 10.7 PAX2 PAX8
36 bile duct cystadenocarcinoma 10.6 KRT20 KRT7
37 childhood endodermal sinus tumor 10.6 PAX2 PAX8
38 mucinous ovarian cystadenoma 10.6 CDX2 KRT7
39 intratubular embryonal carcinoma 10.6 KRT20 KRT7
40 renal adenoma 10.6 KRT7 PAX2
41 meibomian cyst 10.6 KRT20 KRT7
42 bladder lymphoma 10.6 KRT20 KRT7
43 mixed cell type cancer 10.6 KRAS KRT7
44 papillary serous adenocarcinoma 10.6 KRT20 KRT7
45 nasal cavity squamous cell carcinoma 10.6 CDKN2A KRT7
46 medulloepithelioma 10.6 KRT20 KRT7
47 paget disease, extramammary 10.6 KRT20 KRT7
48 ovary adenocarcinoma 10.5 KRAS KRT7
49 mucinous cystadenocarcinoma 10.5 KRT20 KRT7
50 urethral diverticulum 10.5 KRT7 PAX8

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ

Symptoms & Phenotypes for Adenocarcinoma in Situ

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CLDN1 KRAS KRT7 MCM2 PAX8 TOP2A

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.92 MCM2 PAX2 PAX8 CDKN1A CDKN2A CDX2
2 embryo MP:0005380 9.8 MCM2 PAX2 PAX8 CDKN1A CDKN2A CDX2
3 endocrine/exocrine gland MP:0005379 9.7 MCM2 PAX2 PAX8 CDKN1A CDKN2A CDX2
4 neoplasm MP:0002006 9.35 MCM2 CDKN1A CDKN2A CDX2 KRAS
5 pigmentation MP:0001186 8.92 MCM2 PAX2 CDKN2A KRAS

Drugs & Therapeutics for Adenocarcinoma in Situ

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Cervarix 18 49 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline October 2009
2
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 26)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
2
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
3 Adjuvants, Immunologic Phase 3
4 Gastrointestinal Agents Phase 3
5 Antacids Phase 3
6 Antibodies Phase 3,Phase 2
7 Immunoglobulins Phase 3,Phase 2
8 Anti-Ulcer Agents Phase 3
9
Metformin Approved Phase 2 657-24-9 14219 4091
10
nivolumab Approved Phase 2 946414-94-4
11
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
12
Testosterone Approved, Investigational Phase 1, Phase 2 58-22-0 6013
13 Hypoglycemic Agents Phase 2
14 Antibodies, Monoclonal Phase 2
15 Alkylating Agents Phase 1, Phase 2
16 Androgens Phase 1, Phase 2
17 Hormone Antagonists Phase 1, Phase 2
18 Hormones Phase 1, Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
20 Immunosuppressive Agents Phase 1, Phase 2
21 Antirheumatic Agents Phase 1, Phase 2
22 Antineoplastic Agents, Alkylating Phase 1, Phase 2
23
Proflavine Approved Not Applicable 92-62-6 7099
24 Pharmaceutical Solutions Not Applicable
25 Anti-Infective Agents Not Applicable
26 Anti-Infective Agents, Local Not Applicable

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
2 Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) Unknown status NCT01429649 Phase 3
3 Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants Completed NCT00128661 Phase 3
4 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
5 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Completed NCT00834106 Phase 3
6 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Completed NCT00779766 Phase 3
7 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
8 Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study Completed NCT00929526 Phase 3
9 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older Completed NCT00294047 Phase 3
10 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed NCT01461096 Phase 3
11 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
12 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
13 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
14 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Recruiting NCT03546842 Phase 3
15 Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
16 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213) Not yet recruiting NCT03493542 Phase 3
17 Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) Completed NCT00365716 Phase 2
18 V501 Efficacy Study in Women Aged 18 to 26 (V501-027) Completed NCT00378560 Phase 2
19 Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil Completed NCT00518336 Phase 2
20 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer Recruiting NCT03053544 Phase 2 Metformin
21 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
22 A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer Active, not recruiting NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
23 Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease Completed NCT00709891 Not Applicable
24 Randomized Controlled Trial of Human Papillomavirus Testing in Primary Cervical Cancer Screening Completed NCT00479375 Not Applicable
25 Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study Completed NCT02323997
26 In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer? Recruiting NCT02937155
27 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing Recruiting NCT02705404
28 Treatment of Multifocal Lung Adenocarcinoma Recruiting NCT01946100 Not Applicable
29 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Not Applicable Proflavine
30 Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Active, not recruiting NCT02653118
31 Evaluation of Long-term HPV Vaccine Efficacy Enrolling by invitation NCT01393470
32 A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects Not yet recruiting NCT03438006
33 Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC Not yet recruiting NCT03216551
34 Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer Suspended NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Genetic Tests for Adenocarcinoma in Situ

Anatomical Context for Adenocarcinoma in Situ

MalaCards organs/tissues related to Adenocarcinoma in Situ:

41
Cervix, Lung, Testes, Prostate, Colon, Lymph Node, Ovary

Publications for Adenocarcinoma in Situ

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 274)
# Title Authors Year
1
Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube. ( 29670794 )
2018
2
Thoracoscopic total esophagogastrectomy with supercharged colon interposition for the treatment of esophageal adenocarcinoma in situs inversus. ( 29436979 )
2018
3
A case of urachal villous adenoma with high grade dysplasia focally bordering on adenocarcinoma in situ. ( 29321972 )
2018
4
Adenocarcinoma in situ admixed with small cell neuroendocrine carcinoma of the cervix: A case report with cytological features. ( 29656585 )
2018
5
HRCT texture analysis for pure or part-solid ground-glass nodules: distinguishability of adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma. ( 29273964 )
2018
6
Oncological and reproductive outcomes of adenocarcinoma in situ of the cervix managed with the loop electrosurgical excision procedure. ( 29690868 )
2018
7
Is a 5-mm diameter an appropriate cut-off value for the diagnosis of atypical adenomatous hyperplasia and adenocarcinoma in situ on chest computed tomography and pathological examination? ( 29780625 )
2018
8
Anal gland adenocarcinoma in situ with pagetoid spread: a case report. ( 29943205 )
2018
9
Response to: Cutaneous papillary adenocarcinoma in situ. ( 28299799 )
2017
10
Adenocarcinoma In Situ Arising from Brunner's Gland Treated by Endoscopic Mucosal Resection. ( 28512587 )
2017
11
Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )
2017
12
Risk of persistent or recurrent cervical neoplasia in patients with 'pure' adenocarcinoma-in-situ (AIS) or mixed AIS and high-grade cervical squamous neoplasia (cervical intra-epithelial neoplasia grades 2 and 3 (CIN 2/3)): a population-based study. ( 28678394 )
2017
13
False-Negative Interpretation of Adenocarcinoma In Situ in the College of American Pathologists Gynecologic PAP Education Program. ( 28301226 )
2017
14
Two cases of adenocarcinoma in situ arising in lobular endocervical glandular hyperplasia indicating localization of mucin on the cluster surface as an early cytological finding of malignant transformation. ( 28449203 )
2017
15
Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ. ( 28821955 )
2017
16
HPV-negative Gastric Type Adenocarcinoma In Situ of the Cervix: A Spectrum of Rare Lesions Exhibiting Gastric and Intestinal Differentiation. ( 28394803 )
2017
17
Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )
2017
18
Mini-laparoscopic hysterectomy for adenocarcinoma in situ of the uterine cervix using interchangeable 5-mm end effectors: a way to cross the line of minimally invasive surgery in gynaecologic oncology. ( 29479402 )
2017
19
Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. ( 28125627 )
2017
20
Human Papillomavirus-Associated Adenocarcinoma In Situ of the Vestibule. ( 28953132 )
2017
21
Cutaneous papillary adenocarcinoma in situ. ( 28164358 )
2017
22
Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies. ( 27565930 )
2016
23
Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. ( 27174588 )
2016
24
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. ( 27137345 )
2016
25
Case of anal adenocarcinoma in situ with pagetoid spread but without macroscopic abnormality in anal mucosa. ( 27666572 )
2016
26
Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases. ( 27334141 )
2016
27
Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung. ( 27597281 )
2016
28
Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ. ( 27908632 )
2016
29
Syringocystadenocarcinoma Papilliferum In Situ, a Variant of Cutaneous Adenocarcinoma In Situ: A Case Report With Literature Review. ( 27533073 )
2016
30
Thin-section computed tomography-histopathologic comparisons of pulmonary focal interstitial fibrosis, atypical adenomatous hyperplasia, adenocarcinoma in situ, and minimally invasive adenocarcinoma with pure ground-glass opacity. ( 27666606 )
2016
31
Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. ( 27174927 )
2016
32
Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma-analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. ( 27067781 )
2016
33
Endocervical adenocarcinoma in situ presenting in fundal endometrial polyp: the mother of all skip lesions. ( 25844546 )
2015
34
Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? ( 25769659 )
2015
35
Extrafascial Hysterectomy Without Preoperative Conization is Unacceptable in Patients With Adenocarcinoma in Situ Diagnosed by Cervical Punch Biopsy or Endocervical Curettage. ( 27679125 )
2015
36
Laparoscopic Oophorectomy and Radical Lymph Node Dissection for a Recurrent Adenocarcinoma In Situ of the Cervix. ( 27678792 )
2015
37
Cytological Diagnoses of Adenocarcinoma in situ of the Cervix: Common Misdiagnoses. ( 25766846 )
2015
38
Cytological variations and typical diagnostic features of endocervical adenocarcinoma in situ: A retrospective study of 74 cases. ( 25972909 )
2015
39
Conservative Treatment Seems the Best Choice in Adenocarcinoma In Situ of the Cervix Uteri. ( 25943864 )
2015
40
Coexistence of mature cystic teratoma and adenocarcinoma in situ within atypical proliferative mucinous tumour of ovary--a case report of 35-year-old woman. ( 26050362 )
2015
41
Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. ( 25970685 )
2015
42
Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA). ( 26503035 )
2015
43
Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. ( 25987897 )
2015
44
The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. ( 25956340 )
2015
45
Prognosis and status of lymph node involvement in patients with adenocarcinoma in situ and minimally invasive adenocarcinoma-a systematic literature review and pooled-data analysis. ( 26716039 )
2015
46
Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4A years after sublobar resection for adenocarcinoma in situ: report of a case. ( 25377270 )
2014
47
Clinical outcomes of patients with adenocarcinoma in situ of the cervix treated by conization. ( 25556268 )
2014
48
Papillary adenocarcinoma in situ of the skin: report of four cases. ( 24855569 )
2014
49
Adenocarcinoma in situ of the uterine cervix-a systematic review. ( 25238167 )
2014
50
Can adenocarcinoma in situ of the uterine cervix be treated safely by conisation in combination with endocervical curettage? ( 25556275 )
2014

Variations for Adenocarcinoma in Situ

Expression for Adenocarcinoma in Situ

Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Pathways for Adenocarcinoma in Situ

GO Terms for Adenocarcinoma in Situ

Cellular components related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.02 CDKN1A CDKN2A MCM2 PAX2 TOP2A

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 G1/S transition of mitotic cell cycle GO:0000082 9.72 CDKN1A CDKN2A MCM2
2 Ras protein signal transduction GO:0007265 9.71 CDKN1A CDKN2A KRAS
3 cochlea development GO:0090102 9.62 MCM2 PAX2
4 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.61 CDKN1A CDKN2A
5 cellular senescence GO:0090398 9.61 CDKN1A CDKN2A
6 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.6 PAX2 PAX8
7 negative regulation of phosphorylation GO:0042326 9.59 CDKN1A CDKN2A
8 positive regulation of cellular senescence GO:2000774 9.58 CDKN2A KRAS
9 urogenital system development GO:0001655 9.58 PAX2 PAX8
10 mesonephros development GO:0001823 9.57 PAX2 PAX8
11 replicative senescence GO:0090399 9.56 CDKN1A CDKN2A
12 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.52 PAX2 PAX8
13 pronephros development GO:0048793 9.51 PAX2 PAX8
14 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.49 PAX2 PAX8
15 metanephric epithelium development GO:0072207 9.48 PAX2 PAX8
16 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.46 PAX2 PAX8
17 metanephric nephron tubule formation GO:0072289 9.43 PAX2 PAX8
18 metanephric distal convoluted tubule development GO:0072221 9.4 PAX2 PAX8
19 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.37 PAX2 PAX8
20 pronephric field specification GO:0039003 9.32 PAX2 PAX8
21 positive regulation of metanephric DCT cell differentiation GO:2000594 9.26 PAX2 PAX8
22 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.16 PAX2 PAX8
23 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 8.96 PAX2 PAX8
24 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 8.62 PAX2 PAX8

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN1A CDKN2A

Sources for Adenocarcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....